The use of non-nucleoside reverse transcriptase inhibitors in the treatment of HIV-1 infection

Thesis (complete)

Front cover

Propositions as part of the thesis

Title pages

Contents

CHAPTER 1 INTRODUCTION

CHAPTER 2 COMPARISON OF FIRST-LINE ANTIRETROVIRAL THERAPY WITH REGIMENS INCLUDING NEVIRAPINE, EFAVIRENZ, OR BOTH DRUGS, PLUS STAVUDINE AND LAMIVUDINE: A RANDOMISED OPEN-LABEL TRIAL, THE 2NN STUDY

CHAPTER 3 THE EFFECT OF BASELINE CD4 CELL COUNT AND HIV-1 VIRAL LOAD ON THE EFFICACY AND SAFETY OF NEVIRAPINE OR EFAVIRENZ BASED FIRST-LINE HAART

CHAPTER 4 PLASMA HIV-1 RNA DECLINE WITHIN THE FIRST 2 WEEKS OF TREATMENT IS COMPARABLE FOR NEVIRAPINE, EFAVIRENZ, OR BOTH DRUGS COMBINED AND IS NOT PREDICTIVE OF LONG-TERM VIROLOGIC FAILURE

CHAPTER 5 PHARMACOKINETIC PARAMETERS OF NEVIRAPINE AND EFAVIRENZ IN RELATION TO VIROLOGIC FAILURE

CHAPTER 6 QUALITY OF LIFE IN PATIENTS TREATED WITH FIRST-LINE ANTIRETROVIRAL THERAPY CONTAINING NEVIRAPINE AND/OR EFAVIRENZ

CHAPTER 7 DIFFERENTIAL CD4+ T CELL RESPONSE IN HIV-1 INFECTED PATIENTS USING PROTEASE INHIBITOR OR NEVIRAPINE BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY

CHAPTER 8 NEVIRAPINE AND EFAVIRENZ ELICIT DIFFERENT CHANGES IN LIPID PROFILES IN ANTIRETROVIRAL THERAPY-NAIVE PATIENTS INFECTED WITH HIV-1

CHAPTER 9 LIPID PROFILES IN HIV-INFECTED PATIENTS RECEIVING COMBINATION ANTIVIRAL THERAPY: ARE DIFFERENT ANTIRETROVIRAL DRUGS ASSOCIATED WITH DIFFERENT LIPID PROFILES?

CHAPTER 10 DISCUSSION

CHAPTER 11 SUMMARY, NEDERLANDSE SAMENVATTING

CHAPTER 12 WORD OF THANKS, PUBLICATIONS, CURRICULUM VITAE

Back cover